NASDAQ: PRTC - PureTech Health plc

छह महीने के लिए लाभप्रदता: -14.52%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम PureTech Health plc


कंपनी के बारे में PureTech Health plc

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.

अधिक जानकारी
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

IPO date 2020-11-16
ISIN US7462371060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.puretechhealth.com
Цена ао 16.75
प्रति दिन मूल्य परिवर्तन: -0.4407% (17.7)
प्रति सप्ताह मूल्य परिवर्तन: +5.47% (16.7088)
प्रति माह मूल्य परिवर्तन: -6.71% (18.89)
3 महीने में कीमत में बदलाव: -9.68% (19.51)
छह महीने में कीमत में बदलाव: -14.52% (20.615)
प्रति वर्ष मूल्य परिवर्तन: -38.17% (28.5)
3 वर्षों में मूल्य परिवर्तन: -38.77% (28.78)
वर्ष की शुरुआत से मूल्य परिवर्तन: -9.68% (19.51)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 211.58 1
P/BV 1.24 9
P/E 0 0
EV/EBITDA -3.8 0
कुल: 3.63

क्षमता

नाम अर्थ श्रेणी
ROA, % -9.47 0
ROE, % -14.16 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0.0657

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.1806 10
कुल: 9.6

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % -61.72 0
लाभप्रदता Ebitda, % -87.75 0
लाभप्रदता EPS, % -101.65 0
कुल: 0

संस्थानों आयतन शेयर करना, %
Pentwater Capital Management LP 10244 0.04
Tower Research Capital LLC (TRC) 43 0
UBS Group AG 20 0

ETF शेयर करना, % वर्ष के लिए लाभप्रदता, % लाभांश, %
Amplify BlueStar Israel Technology ETF 0.30643 20.42 0.47569
Invesco Global Listed Private Equity ETF 0.29338 29.43 3.4983
Dimensional International Small Cap ETF 0.02653 5.69 3.34747
SPDR S&P International Small Cap ETF 0.0233 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0133 10.07 3.20638
SPDR Portfolio Europe ETF 0.00347 8.94 3.66537
Dimensional International Core Equity 2 ETF 0.00136 6.52 3.69996
Avantis International Equity ETF 0.00099 6.46 3.80856
Dimensional International Core Equity Market ETF 0.00032 13.09 3.48343
Vanguard FTSE All-World ex-US Small-Cap ETF 0 9.39 3.09932
Vanguard ESG International Stock ETF 0 6.39 3.07501



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M 1971 (54 वर्ष)
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M 1965 (60 साल)
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor N/A 1948 (77 साल)
Ms. Allison Mead Talbot Head of Communications & Investor Relations N/A
Mr. Spencer Ball Senior Vice President of Human Resources N/A
Dr. Eric Elenko Ph.D. Co-Founder & President N/A 1973 (52 वर्ष)
Mr. Eric Green M.B.A. Chief Operating Officer N/A
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary N/A
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 1949 (76 साल)
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance

पता: United States, Boston. MA, 6 Tide Street - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.puretechhealth.com